The Index
Every company in our coverage — the builders, studios and houses we write about. Each one gathers its articles, jobs and listings in a single place.
7 companies
Biopharma
A single-asset MASH/AUD/ALD bet on a glucagon/GLP-1 dual agonist that wins on liver biology and lean-mass-sparing but loses on raw weight loss — fully funded into 2028 with a binary AUD readout in Q3 2026 as the next free option; a derisked, heavily-shorted optionality vehicle, not a fundamentals compounder.
Biopharma
A levered dividend-compounder running a patent-cliff relay race — the legacy book (>40% of revenue under biosimilar/IRA attack) is being out-sprinted by Repatha/rare-disease/oncology launches, but the equity is priced for MariTide to win the obesity prize it most likely places, not wins, in.